株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

インフルエンザ診断の世界市場の予測 ~2021年:従来型診断 (RIDT・ウイルス培養・DFA・血清学的検査)・分子診断 (RT-PCR・NASBA・LAMP・SAMBA)

Influenza Diagnostics Market by Test type (Traditional (Rapid Influenza Detection Test, Viral Culture, DFA, Serology Test), Molecular (RT-PCR, NASBA, LAMP, SAMBA)), End user - Global Forecast to 2021

発行 MarketsandMarkets 商品コード 450006
出版日 ページ情報 英文 130 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.20円で換算しております。
Back to Top
インフルエンザ診断の世界市場の予測 ~2021年:従来型診断 (RIDT・ウイルス培養・DFA・血清学的検査)・分子診断 (RT-PCR・NASBA・LAMP・SAMBA) Influenza Diagnostics Market by Test type (Traditional (Rapid Influenza Detection Test, Viral Culture, DFA, Serology Test), Molecular (RT-PCR, NASBA, LAMP, SAMBA)), End user - Global Forecast to 2021
出版日: 2017年02月23日 ページ情報: 英文 130 Pages
概要

世界のインフルエンザ診断市場は2016年から2021年にかけて8.6%のCAGR (年間複合成長率) で推移し、2016年の5億800万米ドルから、2021年には7億6740万米ドルの規模に成長すると予測されています。

当レポートでは、世界のインフルエンザ診断の市場を調査し、市場および製品の概要、市場成長への各種影響因子および市場機会の分析、法規制環境、検査タイプ・エンドユーザー・地域/主要国別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

FIGURE 11 INFLUENZA DIAGNOSTICS MARKET

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

  • 市場概要
  • 従来型検査市場の実績:地域・タイプ別
  • 分子診断検査市場の実績・予測:タイプ別
  • ライフサイクル分析:地域別

第5章 市場概要

  • イントロダクション
  • 市場成長促進要因
  • 市場成長抑制要因
  • 市場機会
  • 課題
  • 法規制上の枠組み

第6章 インフルエンザ診断市場:検査タイプ別

  • イントロダクション
  • 従来型診断検査
    • インフルエンザ迅速診断テスト (RIDT)
    • ウイルス培養
    • 直接蛍光抗体 (DFA) 検査
    • 血清学的検査
  • 分子診断検査
    • RT-PCR
    • NASBA法
    • LAMP法
    • SAMBA法
    • その他

第7章 インフルエンザ診断市場:エンドユーザー別

  • イントロダクション
  • 病院/臨床ラボ
  • リファレンスラボラトリー
  • その他

第8章 インフルエンザ診断市場:地域市場

  • イントロダクション
  • PEST分析
  • 欧州
    • ドイツ
    • 英国
    • その他
  • 北米
    • 米国
    • カナダ
  • アジア太平洋
  • その他の地域

第9章 競合環境

  • 概要
  • 主要企業
  • 競合状況・動向
    • 製品の投入・承認
    • 買収
    • 拡張
    • 提携・合意

第10章 企業プロファイル

  • イントロダクション
  • F. HOFFMANN-LA ROCHE AG
  • BECTON, DICKINSON AND COMPANY
  • THERMO FISHER SCIENTIFIC INC.
  • ALERE INC.
  • DIASORIN S.P.A.
  • QUIDEL CORPORATION
  • MERIDIAN BIOSCIENCE, INC.
  • ANALYTIK JENA AG
  • LUMINEX CORPORATION
  • SA SCIENTIFIC, LTD.
    • 事業概要
    • 製品・サービス
    • 近年の発展動向
    • SWOT分析、など

第11章 付録

目次
Product Code: BT 5027

The global influenza diagnostics market is expected to reach USD 767.4 million by 2021 from USD 508.0 million in 2016, at a CAGR of 8.6% from 2016 to 2021. On the basis of test type, the market is segmented into traditional and molecular diagnostic tests. The traditional diagnostic tests segment is further categorized into rapid influenza detection tests (RIDT), viral culture, direct fluorescent antibody (DFA) tests, and serological assays. In 2016, the RIDT segment is expected to account for the largest share of the traditional tests market owing to factors such as its user-friendliness, rapid generation of results, and easy interpretability. The molecular diagnostic tests segment is further divided into RT-PCR, nucleic acid sequence-based amplification (NASBA) tests, loop-mediated isothermal amplification-based assays (LAMP), and simple amplification-based assays (SAMBA). In 2016, the RT-PCR segment is expected to hold the largest share of the molecular diagnostic tests market due to its ability to detect and distinguish between influenza A and B viruses with high specificity.

  • On the basis of end user, the influenza diagnostics market is segmented into hospitals/clinical laboratories, reference laboratories, and other end users (point-of-care testing, home health agencies, and nursing homes). The hospitals/clinical laboratories end-user segment is expected to dominate the influenza diagnostics market in 2016. The large share of this segment can be attributed to the fact that most influenza disease diagnostic tests are carried out in hospitals and clinical laboratories, as these tests are highly complex in nature and require the use of specialized instruments.
  • On the basis of region, the market is segmented into North America, Europe, Asia-Pacific, and RoW. In 2016, the European region is expected to account for the largest share of the market due to the rapidly increasing prevalence of influenza and rise in aging population in Europe.

The increasing prevalence of influenza, growth in research funding for influenza diagnostics, and rising demand for rapid and effective disease diagnosis and treatment are the key factors driving the growth of the global influenza diagnostics market.

Research Coverage:

This report studies the influenza diagnostics market based on test type, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, future prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions

Reasons to Buy the Report:

The report will enable both established firms and new entrants to gauge the pulse of the market and to help them make important strategic growth decisions.

The report provides insights on the following:

  • Product Development/Innovation: Product portfolios of the top players in the influenza diagnostics market. Detailed insights on upcoming technologies, research and development activities, and new product launches in the insights on upcoming technologies market
  • Competitive Assessment: In-depth assessment of market shares, strategies, geographic and business segments, and product portfolios of the leading players in the influenza diagnostics market
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the market for various influenza diagnostic tests across geographies
  • Market Diversification: Exhaustive information about new products, recent developments, and investments in the influenza diagnostics market

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
    • 1.2.1. MARKETS COVERED
    • 1.2.2. YEARS CONSIDERED IN THE REPORT
  • 1.3. CURRENCY
  • 1.4. LIMITATIONS
  • 1.5. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. MARKET SIZE ESTIMATION
  • 2.2. MARKET RANKING ANALYSIS
  • 2.3. MARKET BREAKDOWN AND DATA TRIANGULATION
    • 2.3.1. KEY DATA FROM SECONDARY SOURCES
    • 2.3.2. KEY DATA FROM PRIMARY SOURCES
    • 2.3.3. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

  • 3.1. INTRODUCTION
  • 3.2. CONCLUSION

4. PREMIUM INSIGHTS

  • 4.1. INFLUENZA DIAGNOSTICS: MARKET OVERVIEW
  • 4.2. GEOGRAPHIC ANALYSIS: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE (2016)
  • 4.3. MOLECULAR DIAGNOSTIC TESTS MARKET SIZE, BY TYPE, 2016 VS. 2021(USD MILLION)
  • 4.4. LIFE CYCLE ANALYSIS, BY REGION (2016)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. DRIVERS
    • 5.2.1. INCREASING PREVALENCE OF INFLUENZA
    • 5.2.2. GROWTH IN RESEARCH FUNDING FOR INFLUENZA DIAGNOSTICS
    • 5.2.3. RISING DEMAND FOR FASTER DIAGNOSIS AND CONTROL OF INFLUENZA
  • 5.3. RESTRAINTS
    • 5.3.1. VARIABILITY IN SENSITIVITY AND SPECIFICITY AMONG INFLUENZA DIAGNOSTIC TESTS
    • 5.3.2. STRINGENT REGULATORY FRAMEWORK
    • 5.3.3. RISING HEALTHCARE COSTS LIMITING THE USAGE OF NOVEL INFLUENZA DIAGNOSTIC TECHNIQUES
  • 5.4. OPPORTUNITIES
    • 5.4.1. ADVANCEMENTS IN GENOMIC AND PROTEOMIC TECHNOLOGIES
    • 5.4.2. SIGNIFICANT GROWTH PROSPECTS IN DEVELOPING COUNTRIES
  • 5.5. CHALLENGE
    • 5.5.1. DEARTH OF SKILLED PERSONNEL TO HANDLE ADVANCED INFLUENZA DIAGNOSTIC TOOLS
  • 5.6. REGULATORY FRAMEWORK
    • 5.6.1. NORTH AMERICA
    • 5.6.2. EUROPE
    • 5.6.3. ASIA-PACIFIC
      • 5.6.3.1. India
      • 5.6.3.2. China
      • 5.6.3.3. Australia

6. INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE

  • 6.1. INTRODUCTION
  • 6.2. TRADITIONAL DIAGNOSTIC TESTS
    • 6.2.1. RAPID INFLUENZA DETECTION TESTS (RIDT)
    • 6.2.2. VIRAL CULTURE
    • 6.2.3. DIRECT FLUORESCENT ANTIBODY (DFA) TESTS
    • 6.2.4. SEROLOGICAL ASSAYS
  • 6.3. MOLECULAR DIAGNOSTIC TESTS
    • 6.3.1. RT-PCR
    • 6.3.2. NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION (NASBA) TESTS
    • 6.3.3. LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS (LAMP)
    • 6.3.4. SIMPLE AMPLIFICATION-BASED ASSAYS (SAMBA)
    • 6.3.5. OTHER MOLECULAR DIAGNOSTIC TESTS

7. INFLUENZA DIAGNOSTICS MARKET, BY END USER

  • 7.1. INTRODUCTION
  • 7.2. HOSPITALS/CLINICAL LABORATORIES
  • 7.3. REFERENCE LABORATORIES
  • 7.4. OTHER END USERS

8. INFLUENZA DIAGNOSTICS MARKET, BY REGION

  • 8.1. INTRODUCTION
  • 8.2. PEST ANALYSIS
    • 8.2.1. POLITICAL FACTORS
    • 8.2.2. ECONOMIC FACTORS
    • 8.2.3. SOCIOCULTURAL FACTORS
    • 8.2.4. TECHNOLOGICAL FACTORS
  • 8.3. EUROPE
    • 8.3.1. GERMANY
    • 8.3.2. U.K.
    • 8.3.3. REST OF EUROPE
  • 8.4. NORTH AMERICA
    • 8.4.1. U.S.
    • 8.4.2. CANADA
  • 8.5. ASIA-PACIFIC
  • 8.6. REST OF THE WORLD (ROW)

9. COMPETITIVE LANDSCAPE

  • 9.1. OVERVIEW
  • 9.2. LEADING PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET
  • 9.3. COMPETITIVE SITUATION AND TRENDS
    • 9.3.1. PRODUCT LAUNCHES AND APPROVALS
    • 9.3.2. ACQUISITIONS
    • 9.3.3. EXPANSIONS
    • 9.3.4. COLLABORATIONS AND AGREEMENTS

10. COMPANY PROFILES (Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, Ratio Analysis, MnM View)*

  • 10.1. INTRODUCTION
  • 10.2. F. HOFFMANN-LA ROCHE AG
  • 10.3. BECTON, DICKINSON AND COMPANY
  • 10.4. THERMO FISHER SCIENTIFIC INC.
  • 10.5. ALERE INC.
  • 10.6. DIASORIN S.P.A.
  • 10.7. QUIDEL CORPORATION
  • 10.8. MERIDIAN BIOSCIENCE, INC.
  • 10.9. ANALYTIK JENA AG (A SUBSIDIARY OF ENDRESS+HAUSER AG)
  • 10.10. LUMINEX CORPORATION
  • 10.11. SA SCIENTIFIC, LTD.

*Details on Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

11. APPENDIX

  • 11.1. INSIGHTS OF INDUSTRY EXPERTS
  • 11.2. DISCUSSION GUIDE
  • 11.3. OTHER DEVELOPMENTS
  • 11.4. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 11.5. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 11.6. AVAILABLE CUSTOMIZATIONS
  • 11.7. RELATED REPORTS
  • 11.8. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: GLOBAL INFLUENZA DIAGNOSTICS MARKET SUMMARY
  • TABLE 2: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2014-2021 (USD MILLION)
  • TABLE 3: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 4: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 5: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 6: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 7: INFLUENZA DIAGNOSTICS MARKET SIZE FOR RIDT, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 8: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR RIDT, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 9: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR RIDT, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 10: INFLUENZA DIAGNOSTICS MARKET SIZE FOR VIRAL CULTURE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 11: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR VIRAL CULTURE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 12: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR VIRAL CULTURE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 13: INFLUENZA DIAGNOSTICS MARKET SIZE FOR DFA TESTS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 14: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR DFA TESTS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 15: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR DFA TESTS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 16: INFLUENZA DIAGNOSTICS MARKET SIZE FOR SEROLOGICAL ASSAYS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 17: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR SEROLOGICAL ASSAYS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 18: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR SEROLOGICAL ASSAYS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 19: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 20: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR TESTS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 21: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR TESTS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 22: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR TESTS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 23: INFLUENZA DIAGNOSTICS MARKET SIZE FOR RT-PCR, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 24: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR RT-PCR, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 25: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR RT-PCR, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 26: INFLUENZA DIAGNOSTICS MARKET SIZE FOR NASBA, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 27: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR NASBA, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 28: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR NASBA, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 29: INFLUENZA DIAGNOSTICS MARKET SIZE FOR LAMP, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 30: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR LAMP, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 31: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR LAMP, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 32: INFLUENZA DIAGNOSTICS MARKET SIZE FOR SAMBA, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 33: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR SAMBA, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 34: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR SAMBA, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 35: INFLUENZA DIAGNOSTICS MARKET SIZE FOR OTHER MOLECULAR DIAGNOSTIC TESTS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 36: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR OTHER MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 37: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR OTHER MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 38: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 39: INFLUENZA DIAGNOSTICS MARKET SIZE FOR HOSPITALS/CLINICAL LABORATORIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 40: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR HOSPITALS/CLINICAL LABORATORIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 41: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR HOSPITALS/CLINICAL LABORATORIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 42: INFLUENZA DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 43: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 44: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 45: INFLUENZA DIAGNOSTICS MARKET SIZE FOR OTHER END USERS, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 46: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR OTHER END USERS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 47: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR OTHER END USERS, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 48: GLOBAL INFLUENZA DIAGNOSTICS MARKET SIZE, BY REGION, 2014-2021 (USD MILLION)
  • TABLE 49: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 50: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2014-2021 (USD MILLION)
  • TABLE 51: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2014-2021 (USD MILLION)
  • TABLE 52: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 53: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 54: EUROPE: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 55: GERMANY: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2014-2021 (USD MILLION)
  • TABLE 56: GERMANY: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 57: GERMANY: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 58: GERMANY: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 59: U.K.: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2014-2021 (USD MILLION)
  • TABLE 60: U.K.: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 61: U.K.: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 62: U.K.: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 63: ROE: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2014-2021 (USD BILLION)
  • TABLE 64: ROE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 65: ROE: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 66: ROE: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 67: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2014-2021 (USD MILLION)
  • TABLE 68: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 69: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 70: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 71: U.S.: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2014-2021 (USD MILLION)
  • TABLE 72: U.S.: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 73: U.S.: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 74: U.S.: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 75: CANADA: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2014-2021 (USD MILLION)
  • TABLE 76: CANADA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 77: CANADA: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 78: CANADA: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 79: APAC: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2014-2021 (USD BILLION)
  • TABLE 80: APAC: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 81: APAC: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 82: APAC: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 83: ROW: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2014-2021 (USD MILLION)
  • TABLE 84: ROW: INFLUENZA DIAGNOSTICS MARKET SIZE FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 85: ROW: INFLUENZA DIAGNOSTICS MARKET SIZE FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2014-2021 (USD MILLION)
  • TABLE 86: ROW: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2014-2021 (USD MILLION)
  • TABLE 87: RANK OF COMPANIES IN THE INFLUENZA DIAGNOSTICS MARKET, 2015
  • TABLE 88: PRODUCT LAUNCHES AND APPROVALS, 2014-2016
  • TABLE 89: ACQUISITIONS, 2014-2016
  • TABLE 90: EXPANSIONS, 2014-2016
  • TABLE 91: COLLABORATIONS AND AGREEMENTS, 2014-2016

LIST OF FIGURES

  • FIGURE 1: RESEARCH DESIGN
  • FIGURE 2: MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH
  • FIGURE 3: MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • FIGURE 4: BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5: DATA TRIANGULATION METHODOLOGY
  • FIGURE 6: INFLUENZA DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 7: TRADITIONAL DIAGNOSTIC TESTS MARKET SIZE, BY TYPE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 8: MOLECULAR DIAGNOSTIC TESTS MARKET SIZE, BY TYPE, 2016 VS. 2021 (USD MILLION)
  • FIGURE 9: INFLUENZA DIAGNOSTICS MARKET SIZE, BY END USER, 2016 VS. 2021 (USD MILLION)
  • FIGURE 10: GEOGRAPHICAL SNAPSHOT OF THE INFLUENZA DIAGNOSTICS MARKET
  • FIGURE 11: RISING PREVALENCE OF INFLUENZA ACROSS THE GLOBE TO DRIVE THE INFLUENZA DIAGNOSTICS MARKET
  • FIGURE 12: RAPID INFLUENZA DETECTION TESTS TO COMMAND THE LARGEST MARKET SHARE IN 2016
  • FIGURE 13: RT-PCR TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD
  • FIGURE 14: ASIA-PACIFIC PRESENTS LUCRATIVE GROWTH OPPORTUNITIES FOR PLAYERS IN THE GLOBAL INFLUENZA DIAGNOSTICS MARKET
  • FIGURE 15: INFLUENZA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 16: RIDT TO DOMINATE THE TRADITIONAL DIAGNOSTIC TESTS MARKET IN 2016
  • FIGURE 17: RT-PCR TO DOMINATE THE MOLECULAR DIAGNOSTIC TESTS MARKET IN 2016
  • FIGURE 18: HOSPITALS/CLINICAL LABORATORIES TO DOMINATE THE INFLUENZA DIAGNOSTICS END-USER MARKET IN 2016
  • FIGURE 19: GEOGRAPHIC SNAPSHOT: ASIA-PACIFIC TO BE THE FASTEST-GROWING REGION DURING THE FORECAST PERIOD
  • FIGURE 20: EUROPE: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 21: NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 22: COMPANIES MAJORLY PURSUED THE STRATEGY OF PRODUCT LAUNCHES AND APPROVALS BETWEEN 2014 AND 2016
  • FIGURE 23: BATTLE FOR MARKET SHARE: PRODUCT LAUNCHES AND APPROVALS WAS THE KEY STRATEGY ADOPTED BY MARKET PLAYERS IN INFLUENZA DIAGNOSTICS MARKET BETWEEN 2014 AND 2016
  • FIGURE 24: GEOGRAPHIC REVENUE MIX OF THE TOP 5 MARKET PLAYERS (2015)
  • FIGURE 25: F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2015)
  • FIGURE 26: BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2016)
  • FIGURE 27: THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2015)
  • FIGURE 28: ALERE INC.: COMPANY SNAPSHOT (2015)
  • FIGURE 29: DIASORIN S.P.A.: COMPANY SNAPSHOT (2015)
  • FIGURE 30: QUIDEL CORPORATION: COMPANY SNAPSHOT (2015)
  • FIGURE 31: MERIDIAN BIOSCIENCE, INC.: COMPANY SNAPSHOT (2015)
  • FIGURE 32: ANALYTIK JENA AG: COMPANY SNAPSHOT (2014)
  • FIGURE 33: LUMINEX CORPORATION: COMPANY SNAPSHOT (2015)
Back to Top